Frank Dellanna

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

A Randomized Comparison of Ferumoxytol and Iron Sucrose for Treating Iron Deficiency Anemia in Patients with CKD

Iain C. Macdougall, William Strauss, Justin McLaughlin et al. · Clinical Journal of the American Society of Nephrology · 2014 · 100 citations · Full text

Internal filtration--advantage in haemodialysis?

Frank Dellanna, A. Wuepper, C. A. Baldamus · Nephrology Dialysis Transplantation · 1996 · 61 citations · Full text